Oculis Holding AG

NasdaqGM:OCS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🕶 Eyewear

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 983.93 M

Share Price

USD 19.28

Avg Daily Volume

36,771

Change (1 day)

-1.03%

Change (1 year)

64.79%

Change (YTD)

13.41%

Oculis Holding AG Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -61.73 M

Oculis Holding AG Free Cash Flow is USD -61.73 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 6.45% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Oculis Holding AG Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -57.99 M, a 47.20% change year over year.
Oculis Holding AG Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -39.39 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities

NasdaqGM: OCS

Oculis Holding AG

CEO	Dr. Riad Sherif M.B.A., M.D.
IPO Date	May 18, 2021
Location	Switzerland
Headquarters	Bahnhofstrasse 7
Employees	49
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🕶 Eyewear 💊 Pharmaceuticals

Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.